Humacyte (HUMA) Other Non Operating Income (2021 - 2026)
Humacyte (HUMA) posted quarterly Other Non Operating Income of $8.5 million for Q1 2026, down 42.9% year-over-year from $14.9 million in Q1 2025, and up 121.07% quarter-over-quarter from -$40.5 million in Q4 2025.
Humacyte (HUMA) Other Non Operating Income (2021 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Other Non Operating Income for 6 consecutive years, with $8.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 42.9% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at -$28.7 million (down 252.63% YoY), while the FY2025 annual figure was -$22.3 million, down 668.76% from the prior year.
- Other Non Operating Income climbed to $8.5 million in Q1 2026 per HUMA's latest filing, from -$40.5 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $14.9 million in Q1 2025 and bottomed at -$40.5 million in Q4 2025.
- Historically, Other Non Operating Income has averaged -$1.0 million across 5 years, with a median of $9000.0 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 24783.33% in 2025 and fell as far as 1365.89% in 2025.
- Humacyte's Other Non Operating Income stood at $417000.0 in 2022, then sank by 624.46% to -$2.2 million in 2023, then surged by 246.14% to $3.2 million in 2024, then plunged by 1365.89% to -$40.5 million in 2025, then soared by 121.07% to $8.5 million in 2026.
- Business Quant data shows HUMA's Other Non Operating Income at $8.5 million in Q1 2026, -$40.5 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.16 Mn |
| Mar 31, 2026 | 8.53 Mn |
| Dec 31, 2025 | -40.46 Mn |
| Sep 30, 2025 | 4.01 Mn |
| Jun 30, 2025 | -748,000.00 |
| Mar 31, 2025 | 14.93 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | -388,000.00 |
| Mar 31, 2024 | 60,000.00 |
| Dec 31, 2023 | -2.19 Mn |
| Sep 30, 2023 | -135,000.00 |
| Jun 30, 2023 | -2.40 Mn |
| Mar 31, 2023 | -42,000.00 |
| Dec 31, 2022 | 417,000.00 |
| Jun 30, 2021 | 3.30 Mn |